timesofisrael : declared in BiondVax gets €20 million loan for universal flu vaccine

Mainly due to vaccine-virus mismatch, current flu vaccine effectiveness is on average only about 40% in the general population, and in elderly people as low as 9%. The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd., a developer of a universal flu vaccine candidate, said they have reached an €20 million ($22 million) loan agreement that will help the Israeli firm bring its vaccine closer to market. Since it is impossible to predict future mutations, current flu vaccines may target strains that are not represented in the current wave of influenza. M-001 has also shown potential to improve upon current seasonal flu vaccines and to serve as an immediate effective response to new flu pandemic strains. BiondVax's M-001 vaccine candidate is designed to protect against current and future, seasonal and pandemic flu strains.

BiondVax nabs €20M loan to advance universal flu vaccine

RELATED: BiondVax pairs with NIAID to test universal flu vaccine in U.S. PhIICurrently, the Israeli biotech is developing its vaccine in a two-part strategy. Second, the company is also seeking to obtain approval for M-001 as a stand-alone universal flu vaccine. RELATED: Israeli biotech BiondVax gets government help to build flu vaccine manufacturing facilitySeasonal flu vaccine effectiveness currently hovers at around 40% to 50%, but can be as low as 9% in elderly people, according to the CDC. Fresh off a grant from the Israeli government to set up a manufacturing plant for its universal flu vaccine, BiondVax has secured a €20 million ($22 million) loan from the European Investment Bank to advance its work. With the money, BiondVax has the resources to launch phase 3 trials on its universal flu vaccine M-001 and set up a mid-sized manufacturing plant, company CEO Ron Babecoff said in a release.





collected by :Lucy William
To follow all the new news about

VIRUSES and INFECTIONS